Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 660 participants.
Also called NCT07621796
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 660 participants
- Sponsor
- Hackensack Meridian Health
- Registry
-
NCT07621796
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07621796. Randomized; triple masking; primary purpose treatment. Start 2027-01-01 (anticipated); primary completion 2032-01-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant
- Acronym
- ESTER-DOAC
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Intravenous tenecteplase (TNK)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Hackensack Meridian Health
Record details
- Record id
cardio:ct-nct07621796- Content hash
84ab538dc1a6df32ff0b3511137e11a1700298cf0f3d493fc44a2e0875a12f4c